| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
48,775 |
38,927 |
$4.43M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
66,248 |
53,372 |
$4.25M |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
25,492 |
21,296 |
$2.08M |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
19,118 |
16,228 |
$1.60M |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
20,014 |
16,168 |
$1.48M |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
8,834 |
7,547 |
$804K |
| 99070 |
|
105,018 |
85,173 |
$429K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
3,016 |
2,579 |
$333K |
| 92551 |
|
37,520 |
31,694 |
$329K |
| 90686 |
|
21,723 |
16,787 |
$280K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
14,649 |
13,838 |
$225K |
| 96160 |
|
67,132 |
53,672 |
$129K |
| 90670 |
|
8,930 |
7,443 |
$126K |
| 90698 |
|
8,899 |
7,373 |
$116K |
| 90461 |
|
5,433 |
5,158 |
$110K |
| 99173 |
|
35,598 |
30,378 |
$86K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
7,050 |
5,587 |
$67K |
| 96127 |
|
17,831 |
12,577 |
$64K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
2,027 |
1,953 |
$36K |
| 90680 |
|
2,153 |
1,748 |
$30K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
676 |
515 |
$25K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,089 |
880 |
$24K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,557 |
893 |
$23K |
| 99174 |
|
4,202 |
3,756 |
$23K |
| 90633 |
|
1,810 |
1,523 |
$21K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
423 |
385 |
$19K |
| 90656 |
|
897 |
887 |
$18K |
| 90677 |
|
707 |
662 |
$17K |
| 99215 |
Prolong outpt/office vis |
163 |
116 |
$17K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,707 |
1,427 |
$16K |
| 90688 |
|
1,056 |
797 |
$15K |
| 0072A |
|
489 |
402 |
$14K |
| 0071A |
|
581 |
409 |
$14K |
| 99381 |
|
244 |
208 |
$14K |
| 83655 |
|
1,563 |
1,339 |
$14K |
| 99383 |
|
128 |
126 |
$14K |
| 99384 |
|
112 |
110 |
$14K |
| 90744 |
|
1,018 |
861 |
$14K |
| 90651 |
|
1,307 |
1,185 |
$13K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
590 |
575 |
$11K |
| 99051 |
|
2,876 |
2,185 |
$10K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
100 |
97 |
$10K |
| 85018 |
|
6,085 |
5,002 |
$9K |
| 92552 |
|
358 |
306 |
$9K |
| 96161 |
|
3,852 |
3,114 |
$8K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
53 |
52 |
$8K |
| 90620 |
|
183 |
178 |
$7K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
572 |
398 |
$6K |
| 90619 |
|
297 |
283 |
$5K |
| 80061 |
Lipid panel |
687 |
511 |
$5K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
57 |
43 |
$4K |
| 90734 |
|
540 |
458 |
$4K |
| 0002A |
|
75 |
72 |
$2K |
| 91320 |
|
45 |
43 |
$2K |
| 90480 |
|
168 |
162 |
$2K |
| 99382 |
|
16 |
16 |
$2K |
| 90710 |
|
126 |
107 |
$2K |
| D0191 |
|
58 |
58 |
$2K |
| 94760 |
|
1,855 |
1,481 |
$1K |
| 0051A |
|
24 |
24 |
$1K |
| 99072 |
|
18,337 |
10,986 |
$888.28 |
| 99188 |
|
106 |
103 |
$869.70 |
| 36416 |
|
11,401 |
8,542 |
$793.93 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
6,947 |
6,384 |
$676.69 |
| 99000 |
|
7,887 |
6,198 |
$657.96 |
| 0001A |
|
30 |
26 |
$642.60 |
| 90715 |
|
109 |
104 |
$633.31 |
| 0081A |
|
13 |
13 |
$607.23 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
15 |
13 |
$497.53 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
35 |
32 |
$437.35 |
| 85014 |
|
181 |
181 |
$424.20 |
| 90696 |
|
38 |
29 |
$349.41 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
17 |
16 |
$239.85 |
| 90474 |
|
12 |
12 |
$141.84 |
| 90685 |
|
12 |
12 |
$116.44 |
| 99401 |
|
28 |
27 |
$84.82 |
| A7016 |
Dome and mouthpiece, used with small volume ultrasonic nebulizer |
18 |
16 |
$53.25 |
| 99058 |
|
19 |
14 |
$40.00 |
| 90723 |
|
17 |
17 |
$25.16 |
| A7015 |
Aerosol mask, used with dme nebulizer |
17 |
16 |
$12.43 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
17 |
16 |
$3.94 |
| 91307 |
|
1,277 |
953 |
$0.76 |
| 90716 |
|
25 |
25 |
$0.25 |
| 90707 |
|
12 |
12 |
$0.12 |
| 90648 |
|
12 |
12 |
$0.11 |
| 91300 |
|
263 |
192 |
$0.01 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
15 |
14 |
$0.01 |
| 91305 |
|
106 |
94 |
$0.00 |
| G9920 |
Screening performed and negative |
19,020 |
17,509 |
$0.00 |
| G9919 |
Screening performed and positive and provision of recommendations |
147 |
133 |
$0.00 |
| 91308 |
|
35 |
31 |
$0.00 |